Literature DB >> 16160915

Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function.

Gregory D Sempowski1, Charles B Hicks, Joseph J Eron, John A Bartlett, Laura P Hale, Guido Ferrari, Lloyd J Edwards, Susan Fiscus, Barton F Haynes.   

Abstract

A key determinant of T cell dynamics in HIV-1 infection is the status of thymic function. To date, most studies of the impact of HIV-1 on the thymus during early HIV-1 infection have been done in samples collected in the interval of 3-12 months after infection. In this study, we have probed the status of thymic function and peripheral naive T cells in patients with acute HIV-1 infection diagnosed 18-72 days after the onset of symptoms. We found that peripheral CD4 and CD8 T cell proliferation was initially elevated, then waned over time. The fall in T cell proliferation correlated with a reduction in HIV-1 viral RNA levels and a rise in peripheral blood CD4+ CD25+ T cells. In spite of elevated T cell proliferation early on in primary HIV-1 infection, levels of naive phenotype CD4 and CD8 T cells and T cell receptor excision circle positive cells (sjTREC(+)) remained constant. Taken together with the observation that T cell proliferation normally dilutes peripheral T cell episomal sjTREC levels, these data suggested that thymopoiesis contributes to maintenance of the naive T cell pool during the earliest stages of HIV-1 infection (18-72 days).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160915     DOI: 10.1007/s10875-005-5635-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  33 in total

1.  Sexual transmission during the incubation period of primary HIV infection.

Authors:  C D Pilcher; J J Eron; P L Vemazza; M Battegay; T Harr; S Yerly; S Vom; L Perrin
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

2.  Evidence for increased T cell turnover and decreased thymic output in HIV infection.

Authors:  D C Douek; M R Betts; B J Hill; S J Little; R Lempicki; J A Metcalf; J Casazza; C Yoder; J W Adelsberger; R A Stevens; M W Baseler; P Keiser; D D Richman; R T Davey; R A Koup
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

Review 3.  Evidence for thymic function in the elderly.

Authors:  D C Douek; R A Koup
Journal:  Vaccine       Date:  2000-02-25       Impact factor: 3.641

4.  Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis.

Authors:  G Sempowski; J Thomasch; M Gooding; L Hale; L Edwards; E Ciafaloni; D Sanders; J Massey; D Douek; R Koup; B Haynes
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

5.  Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

Authors:  J K Wong; H F Günthard; D V Havlir; Z Q Zhang; A T Haase; C C Ignacio; S Kwok; E Emini; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

Review 6.  T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock.

Authors:  M D Hazenberg; D Hamann; H Schuitemaker; F Miedema
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

7.  Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy.

Authors:  M L Markert; A P Alvarez-McLeod; G D Sempowski; L P Hale; J M Horvatinovich; K J Weinhold; J A Bartlett; T A D'Amico; B F Haynes
Journal:  AIDS Res Hum Retroviruses       Date:  2001-11-20       Impact factor: 2.205

8.  The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study.

Authors:  G G Steinmann; B Klaus; H K Müller-Hermelink
Journal:  Scand J Immunol       Date:  1985-11       Impact factor: 3.487

9.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

10.  CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status.

Authors:  Audrey L Kinter; Margaret Hennessey; Alicia Bell; Sarah Kern; Yin Lin; Marybeth Daucher; Maria Planta; Mary McGlaughlin; Robert Jackson; Steven F Ziegler; Anthony S Fauci
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

View more
  5 in total

1.  Thymopoietic and bone marrow response to murine Pneumocystis pneumonia.

Authors:  Xin Shi; Ping Zhang; Gregory D Sempowski; Judd E Shellito
Journal:  Infect Immun       Date:  2011-02-22       Impact factor: 3.441

2.  Immunologic and virologic events in early HIV infection predict subsequent rate of progression.

Authors:  Anuradha Ganesan; Pratip K Chattopadhyay; Tess M Brodie; Jing Qin; Wenjuan Gu; John R Mascola; Nelson L Michael; Dean A Follmann; Mario Roederer
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

3.  Ablation of thymic export causes accelerated decay of naive CD4 T cells in the periphery because of activation by environmental antigen.

Authors:  Christine Bourgeois; Zhenyue Hao; Klaus Rajewsky; Alexandre J Potocnik; Brigitta Stockinger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

Review 4.  Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection.

Authors:  Lori L Hudson; M Louise Markert; Blythe H Devlin; Barton F Haynes; Gregory D Sempowski
Journal:  Semin Immunol       Date:  2007-11-26       Impact factor: 11.130

5.  Reconciling Longitudinal Naive T-Cell and TREC Dynamics during HIV-1 Infection.

Authors:  Julia Drylewicz; Nienke Vrisekoop; Tendai Mugwagwa; Anne Bregje de Boer; Sigrid A Otto; Mette D Hazenberg; Kiki Tesselaar; Rob J de Boer; José A M Borghans
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.